Abstract 1352
Background
The best use of bone targeted agents (BTAs), i.e. how patients (pts) profit most from treatment, optimal timing of treatment start and frequency of administration as well as duration of treatment is unclear to date.
Methods
Physicians were asked to indicate the criteria they use for the indication and administration of BTAs in pts with bone metastases from solid tumors in Switzerland (physician-related outcomes, PO) during a period of 3 months. Patterns of care (POC) was assessed by questions about reasons for BTA administration, treatment pattern, patient characteristics, and actual treatment. Pts completed a pain and bone-pain related quality of life questionnaire.
Results
PO: Most of the physicians reported to start treatment with BTAs according to current guidelines (70.9%, 61/86). A smaller proportion would first assess the risk (high vs low) for developing skeletal-related events (SREs) to decide about treatment initiation (24.4%, 21/86). Factors contributing to define high risk were former SREs (89.5%, 77/86), lytic bone metastases (87.2%, 75/86), and high burden of disease (67.4%, 58/86), respectively. POC: The majority of the pts have been treated with BTAs immediately after the diagnosis of bone metastases (73.6%, 307/417). The main reasons for treatment with BTAs were high risk of bone complications (43%, 132/307), bone pain (21.8%, 67/307), and location of bone metastases (10.1%, 31/307), respectively. Denosumab was the most frequently used BTA (78.5%; 241/307), and a 3-4 week interval was most common (88.9%; 273/307). SREs were reported in 8.5% of treated vs 7.3% of non-treated pts, and were similar in pts rated as low or as high risk (about 8%).
Conclusions
The majority of the pts was treated according to current guideline recommendations with regard to start and interval of BTA treatment. The number of SREs was low irrespective of BTA treatment or risk classification for SREs, which may reflect a high impact of systemic cancer treatment on SRE reduction, or a selection of the pts according to risk factors not defined as the ones in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
SAKK.
Funding
Amgen.
Disclosure
M.T. Mark: Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Böhringer Ingelheim; Advisory / Consultancy: Takeda; Advisory / Consultancy: BMS. B.J.K. Thuerlimann: Advisory / Consultancy, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Roche; Shareholder / Stockholder / Stock options: Novartis; Advisory / Consultancy: Lilly; Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer. R. von Moos: Advisory / Consultancy: amgen; Advisory / Consultancy: BMS; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract